JP6787894B2 - 組換えアルカリホスファターゼを用いた発作の処置 - Google Patents

組換えアルカリホスファターゼを用いた発作の処置 Download PDF

Info

Publication number
JP6787894B2
JP6787894B2 JP2017529820A JP2017529820A JP6787894B2 JP 6787894 B2 JP6787894 B2 JP 6787894B2 JP 2017529820 A JP2017529820 A JP 2017529820A JP 2017529820 A JP2017529820 A JP 2017529820A JP 6787894 B2 JP6787894 B2 JP 6787894B2
Authority
JP
Japan
Prior art keywords
alkaline phosphatase
composition
use according
recombinant
hpp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017529820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502836A (ja
JP2018502836A5 (enExample
Inventor
マロズサン，アンドレ
デボレ，デニス
リウ−チェン，スーザン
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド, アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2018502836A publication Critical patent/JP2018502836A/ja
Publication of JP2018502836A5 publication Critical patent/JP2018502836A5/ja
Application granted granted Critical
Publication of JP6787894B2 publication Critical patent/JP6787894B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017529820A 2014-12-05 2015-12-04 組換えアルカリホスファターゼを用いた発作の処置 Active JP6787894B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462088025P 2014-12-05 2014-12-05
US62/088,025 2014-12-05
US201562259307P 2015-11-24 2015-11-24
US62/259,307 2015-11-24
PCT/US2015/064003 WO2016090251A1 (en) 2014-12-05 2015-12-04 Treating seizure with recombinant alkaline phosphatase

Publications (3)

Publication Number Publication Date
JP2018502836A JP2018502836A (ja) 2018-02-01
JP2018502836A5 JP2018502836A5 (enExample) 2018-12-20
JP6787894B2 true JP6787894B2 (ja) 2020-11-18

Family

ID=55173939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529820A Active JP6787894B2 (ja) 2014-12-05 2015-12-04 組換えアルカリホスファターゼを用いた発作の処置

Country Status (13)

Country Link
US (2) US10449236B2 (enExample)
EP (1) EP3226891B1 (enExample)
JP (1) JP6787894B2 (enExample)
KR (2) KR20170095278A (enExample)
CN (1) CN107405390A (enExample)
AU (1) AU2015357551B2 (enExample)
BR (1) BR112017011900A2 (enExample)
CA (1) CA2967851C (enExample)
CO (1) CO2017005034A2 (enExample)
ES (1) ES3038086T3 (enExample)
MX (1) MX389350B (enExample)
RU (1) RU2708068C2 (enExample)
WO (1) WO2016090251A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2887039T3 (es) 2004-04-21 2021-12-21 Alexion Pharma Inc Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
ES3038086T3 (en) 2014-12-05 2025-10-09 Alexion Pharma Inc Treating seizure with recombinant alkaline phosphatase
EP3250227A2 (en) 2015-01-28 2017-12-06 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
WO2018035420A1 (en) * 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
CN106591255B (zh) * 2017-01-13 2019-07-02 山东省医药生物技术研究中心 人碱性磷酸酶糖蛋白的癌细胞高效表达系统及其应用
WO2018164995A1 (en) * 2017-03-09 2018-09-13 Alexion Pharmaceuticals, Inc . Glycoprotein manufacturing process
WO2018183720A1 (en) * 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
EP3768302B1 (en) 2018-03-20 2025-05-07 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
EP4275761A3 (en) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
WO2020227263A1 (en) 2019-05-06 2020-11-12 Synthetic Biologics, Inc. Alkaline phosphate-based oncology treatments
IL293616A (en) 2019-12-09 2022-08-01 Alexion Pharma Inc Alkaline phosphatase polypeptides and methods of using them
KR20230117327A (ko) * 2020-09-03 2023-08-08 어빈 에스.와이. 첸 가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터
MX2023009463A (es) 2021-02-12 2023-09-21 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos para su uso.
JP7720105B2 (ja) * 2021-03-23 2025-08-07 学校法人日本医科大学 組織非特異型アルカリホスファターゼの送達のための遺伝子療法構築物およびその使用方法
CN115575646B (zh) * 2022-11-21 2023-04-28 四川大学华西医院 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途
WO2025097067A2 (en) * 2023-11-02 2025-05-08 Be Biopharma, Inc. Engineered cell preparations for treatment of hypophosphatasia

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
DE69108830T2 (de) 1990-04-20 1995-09-14 Hisayuki Matsuo Neue im schwein vorkommende physiologisch aktive peptide.
JP2930380B2 (ja) 1990-07-13 1999-08-03 壽之 松尾 ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
JP3026351B2 (ja) 1990-07-13 2000-03-27 壽之 松尾 ブタｃｎｐ遺伝子及び前駆体蛋白
JP2977159B2 (ja) 1990-09-07 1999-11-10 壽之 松尾 カエル由来新規生理活性ペプチド（カエルｃｎｐ）
JP2977158B2 (ja) 1990-09-07 1999-11-10 壽之 松尾 トリ由来新規生理活性ペプチド（ニワトリｃｎｐ）
JP3026352B2 (ja) 1990-09-11 2000-03-27 壽之 松尾 ラットＣＮＰｃＤＮＡ及び前駆体蛋白
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
AU662155B2 (en) 1991-05-10 1995-08-24 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
WO1994020534A1 (en) 1993-03-03 1994-09-15 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
WO1995005455A1 (en) 1993-08-13 1995-02-23 Rijksuniversiteit Te Groningen Pharmaceutical composition comprising phosphatase or a derivative thereof
BR9407956A (pt) 1993-10-25 1996-11-26 Canji Inc Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
CA2174517C (en) 1993-11-12 2007-01-02 David Lowe Receptor specific atrial natriuretic peptides
US5665704A (en) 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5767239A (en) 1994-06-02 1998-06-16 Boehringer Mannheim Gmbh Process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same
JPH0870875A (ja) 1994-09-05 1996-03-19 Tosoh Corp 組換えアルカリフォスファタ−ゼ融合タンパク質
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6028055A (en) 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
CA2269656A1 (en) 1996-10-22 1998-04-30 Genentech, Inc. Receptor specific brain natriuretic peptide (bnp)
WO2000053755A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of tumor
AU6278298A (en) 1997-02-14 1998-09-08 Salk Institute For Biological Studies, The Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
EP1062229A1 (en) 1998-03-09 2000-12-27 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
CA2245903A1 (en) 1998-09-28 2000-03-28 Mcgill University Use of pex in the treatment of metabolic bone diseases
CA2260376A1 (en) 1999-02-11 2000-08-11 Universite De Montreal New metalloproteases of the neprilysin family
CA2262056A1 (en) 1999-02-24 2000-08-24 Guy Boileau Composition, methods and reagents for the synthesis of a soluble form of human pex
JP2002542304A (ja) 1999-04-28 2002-12-10 ベクトレイムド インコーポレイテッド 酵素的に活性化された重合薬物接合体
SI1105409T1 (sl) 1999-05-17 2006-06-30 Conjuchem Inc Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
JP2000327583A (ja) 1999-05-17 2000-11-28 Medei Sci Puraningu:Kk 骨指向性ホルモン誘導体
DE19942230C2 (de) 1999-09-03 2003-09-25 Wolf-Georg Forssmann Verwendung natriuretischer Peptide als antibiotisch wirksame Subsanzen zur Behandlung von bakteriellen Infektionen
WO2001036620A2 (en) 1999-11-16 2001-05-25 Genzyme Corporation Vectors and transgenies with regulatory elements for gene delivery to the liver
AU2583901A (en) 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
CN1233331C (zh) * 2000-01-10 2005-12-28 李世林 以头部渗透疗法为主治疗癫痫症的药物
JP4237375B2 (ja) 2000-03-31 2009-03-11 アスビオファーマ株式会社 虚血性疾患の処置又は予防に用いる医薬組成物
US20050142217A1 (en) 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
EP1502604A1 (en) 2000-04-26 2005-02-02 Cellegy Pharmaceuticals, Inc Use of nitric oxide mimetics in cancer treatment
IL152428A0 (en) 2000-04-26 2003-05-29 Univ Kingston Formulations and method of using nitric oxide mimetics against a malignant cell phenotype
US6830885B1 (en) 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
CA2418461A1 (en) 2000-08-23 2002-02-28 Biomep Inc. Method and compositions for promoting osteogenesis
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
SK288342B6 (en) 2000-12-07 2016-03-01 Lilly Co Eli GLP-1 fusion proteins
JP2002178279A (ja) 2000-12-12 2002-06-25 Ulvac Japan Ltd 基板搬送方法
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
JP2002246704A (ja) 2001-02-16 2002-08-30 Philips Japan Ltd 電子装置及び回路装置
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
US20020183276A1 (en) 2001-03-23 2002-12-05 Burnham Institute Compositions and methods for modulating bone mineral deposition
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
EP1395293B1 (en) 2001-05-14 2009-07-22 Gbp Ip, Llc Lentiviral vectors encoding clotting factors for gene therapy
CA2453434C (en) 2001-07-16 2009-04-14 Hk Pharmaceuticals, Inc. Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
US20050202442A1 (en) 2003-12-15 2005-09-15 Morris David W. Novel therapeutic targets in cancer
DE60239763D1 (de) 2001-12-20 2011-05-26 Enobia Pharma Inc Knochenpolypeptid-1
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20030158132A1 (en) 2002-01-22 2003-08-21 Genvec, Inc. Method for enhancing bone density or formation
CA2478145A1 (en) 2002-03-06 2003-09-12 Cellegy Pharmaceuticals, Inc. Formulations and methods of using nitric oxide mimetics in cancer treatment
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
WO2003079979A2 (en) 2002-03-18 2003-10-02 Scios Inc. Method for treating congestive heart failure
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
CA2488348A1 (en) 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives
AU2003270427A1 (en) 2002-09-06 2004-03-29 University Of South Florida Cellular delivery of natriuretic peptides
CA2511680A1 (en) 2002-11-18 2004-06-03 Syn X Pharma, Inc. Polyclonal-monoclonal elisa assay for detecting n-terminus probnp
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
WO2004050620A2 (en) 2002-12-03 2004-06-17 Enobia Pharma Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
EP1583554A2 (en) 2003-01-13 2005-10-12 Gudrun Rappold-Hoerbrand Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
WO2004074320A2 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic targets in cancer
US7488713B2 (en) 2004-03-18 2009-02-10 University Of South Florida Cancer treatment using C-type natriuretic peptides
JP2006527190A (ja) 2003-04-17 2006-11-30 サイファージェン バイオシステムズ インコーポレイテッド ナトリウム利尿ペプチドに関連したポリペプチド、並びにこれらの同定および使用法
WO2005007809A2 (en) 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
US7919255B2 (en) 2003-06-17 2011-04-05 Otago Innovation Limited Assessment of skeletal growth using measurements of NT-CNP peptides
ES2354881T3 (es) 2003-06-20 2011-03-18 Mayo Foundation For Medical Education And Research Isoformas de péptido natriurético cerebral.
WO2005052593A1 (en) 2003-10-29 2005-06-09 The University Of Leicester Detection
US7431915B2 (en) 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US7736653B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP1720562A4 (en) 2004-01-15 2009-10-28 Scios Inc METHOD FOR TREATING CARDIAL REMODELING AFTER MYOCARDIAL DAMAGE
US20080182299A1 (en) 2004-01-27 2008-07-31 Compugent Ltd. Novel brain natriuretic peptide variants and methods of use thereof
AU2005207886A1 (en) 2004-01-27 2005-08-11 Compugen Usa, Inc. Novel brain natriuretic peptide variants and methods of use thereof
WO2005087802A2 (en) 2004-03-11 2005-09-22 Genentech, Inc. Process for producing polypeptides
EP3620530A1 (en) 2004-03-31 2020-03-11 Kazuwa Nakao Composition for increasing body height
KR101207155B1 (ko) 2004-03-31 2012-12-04 카즈와 나카오 관절염증 치료제 또는 예방제
JP2005292718A (ja) 2004-04-05 2005-10-20 Furukawa Electric Co Ltd:The 光導波路、光導波路モジュールおよび光導波路の作成方法
ES2887039T3 (es) 2004-04-21 2021-12-21 Alexion Pharma Inc Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
SG152290A1 (en) 2004-05-04 2009-05-29 Univ Singapore Method for expressing sialylated glycoproteins in mammalian cells and cells thereof
EP1750728A4 (en) 2004-05-10 2009-04-29 Novacea Inc PREVENTION AGAINST ARTERIAL RESTENOSIS USING ACTIVE VITAMIN D COMPOUNDS
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US7972593B2 (en) 2004-06-10 2011-07-05 Saint Louis University Delivery of therapeutic agents to the bone
US20070081986A1 (en) 2005-10-07 2007-04-12 Shunji Tomatsu Beta-glucuronidase with an attached short peptide of acidic amino acids
BRPI0512496A (pt) 2004-06-23 2008-03-04 Genzyme Corp processos e composições para o tratamento de doenças policìsticas
WO2006005140A2 (en) 2004-07-15 2006-01-19 The University Of Queensland Proteinaceous compounds and uses therefor
US20090142347A1 (en) 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
WO2006060641A2 (en) 2004-12-01 2006-06-08 Genzyme Corporation Methods for targeted delivery of genetic material to the liver
PL2510942T3 (pl) 2005-04-07 2016-02-29 Cardiorentis Ag Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca
EP1874816A4 (en) 2005-04-26 2010-08-25 Medimmune Inc MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING
US20070042957A1 (en) 2005-08-19 2007-02-22 Mayo Foundation For Medical Education And Research Type v phosphodiesterase inhibitors and natriuretic polypeptides
US7470668B2 (en) 2005-08-24 2008-12-30 Enobia Pharma Inc. Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof
US20070099831A1 (en) 2005-09-06 2007-05-03 Paul Morley Parathyroid hormone analogues and methods of use
US7803901B2 (en) 2005-09-16 2010-09-28 Mayo Foundation For Medical Education And Research Polypeptides with natriuresis activity
WO2007041645A2 (en) 2005-10-03 2007-04-12 Scios Inc. Oxidized human bnp
RU2316334C2 (ru) 2005-12-19 2008-02-10 Медитек Индастриз ЛЛС Способ активации утраченных двигательных функций, а также определения эффективности их восстановления при повреждении центральной нервной системы
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
DK1987178T3 (en) 2006-02-20 2015-04-20 Phylogica Ltd Process for the construction and screening of peptide structure libraries
US7787945B2 (en) * 2006-03-08 2010-08-31 Neuropace, Inc. Implantable seizure monitor
US8784833B2 (en) 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
US8962697B2 (en) 2006-06-30 2015-02-24 Interface Biologics Inc. Bioreponsive polymers
TW200817431A (en) 2006-08-08 2008-04-16 Mayo Foundation Diuretic and natriuretic polypeptides
US7825092B2 (en) 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
EP2295445A1 (en) 2006-09-08 2011-03-16 Mayo Foundation for Medical Education and Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity
EP2615108B1 (en) 2006-09-08 2016-10-26 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and thier uses
EP2081602A2 (en) 2006-10-25 2009-07-29 Amgen Inc. Toxin peptide therapeutic agents
US20100168443A1 (en) 2006-11-02 2010-07-01 University Of Virginia Patent Foundation Ethoid-Containing Compounds, Methods for Preparing Ethoid-Containing Compounds, and Methods of Use
US8987200B2 (en) 2006-11-16 2015-03-24 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
KR100856413B1 (ko) * 2006-12-06 2008-09-04 삼성전자주식회사 정착기 및 이를 포함하는 화상형성장치
US20080181903A1 (en) 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
ATE554395T1 (de) 2007-03-12 2012-05-15 Biomedica Medizinprodukte Gmbh & Co Kg Diagnose septischer komplikationen
EP1985697A1 (en) 2007-04-27 2008-10-29 AM-Pharma B.V. Modified phosphatases
KR20080098216A (ko) 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
ES2619332T3 (es) 2007-05-11 2017-06-26 Alexion Pharmaceuticals, Inc. Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
NZ581395A (en) 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP2162464A1 (en) 2007-06-06 2010-03-17 Boehringer Ingelheim International GmbH Natriuretic fusion proteins
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
US20110077383A1 (en) 2007-07-03 2011-03-31 Medimmune, Llc Hinge domain engineering
AU2008274845A1 (en) 2007-07-06 2009-01-15 Theratechnologies Inc. Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-MSH) and atrial natriuretic protein (ANP) and uses in hypertension and acute kidney injury
EP2171053B1 (en) 2007-07-20 2014-04-23 Mayo Foundation for Medical Education and Research Natriuretic polypeptides
US20090053192A1 (en) 2007-08-10 2009-02-26 Burnham Institute For Medical Research Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
RU2010114040A (ru) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение дезлорелина и мастопана в качестве терапевтического средства
WO2009043457A2 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2185183B1 (en) 2007-09-11 2016-03-16 Cardiopep Pharma GmbH Use of natriuretic peptides for treating angioedema syndromes
RU2010114017A (ru) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Терапевтическое применение натрийуретического пептида в-типа и гормона роста человека 1-43
KR20100056509A (ko) 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
JP5395794B2 (ja) 2007-09-11 2014-01-22 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのガラニンペプチドの使用
US8357656B2 (en) 2007-09-15 2013-01-22 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-C agonists
AR069409A1 (es) 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
WO2009086126A2 (en) 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
CN101322866A (zh) * 2008-01-11 2008-12-17 梁树立 脑深部癫痫放电引导治疗方法与设备
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
PL2277890T3 (pl) 2008-05-23 2016-06-30 Daiichi Sankyo Co Ltd Peptyd zdolny do wydłużenia czasu półtrwania w osoczu peptydu będącego przedmiotem zainteresowania
CA2727085A1 (en) 2008-06-06 2009-12-10 Mayo Foundation For Medical Education And Research Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
WO2009156481A1 (en) 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
US20100015144A1 (en) 2008-06-26 2010-01-21 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
EP2307447B1 (en) 2008-07-02 2016-03-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides with unique pharmacologic profiles
RU2483081C2 (ru) 2008-07-23 2013-05-27 Ханми Сайенс Ко.,Лтд.,Kr Полипептидный комплекс, содержащий непептидильный полимер, обладающий тремя функциональными концами
US20100093678A1 (en) 2008-10-10 2010-04-15 The University Of Georgia Research Foundation, Inc Compositions and methods of the treatment of obesity and osteoporosis
US8642550B2 (en) 2008-10-24 2014-02-04 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides without hypotensive inducing capability
WO2010078325A2 (en) 2008-12-29 2010-07-08 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
WO2010082804A2 (en) 2009-01-19 2010-07-22 Hanmi Pharm. Co., Ltd. Method for producing physiologically active protein or peptide using immunoglobulin fragment
EP2413969A4 (en) 2009-03-30 2012-09-05 Boehringer Ingelheim Int FUSION PROTEINS WITH DOG FC ELEMENTS
US20120053123A1 (en) 2009-05-05 2012-03-01 Mayo Foundation For Medical Education And Research Natriuretic polypeptides having mutations within their disulfide rings
DK2432489T3 (en) 2009-05-20 2017-01-16 Biomarin Pharm Inc VARIETIES OF C-TYPE NATRIURETIC PEPTID
US8685024B2 (en) 2010-04-14 2014-04-01 Arrowhead Medical Device Technologies, Llc Intramedullary fixation device and methods for bone fixation and stabilization
KR20130118203A (ko) * 2010-04-30 2013-10-29 알렉시온 파마 인터내셔널 에스에이알엘 매트릭스 무기물화 장애의 처리방법, 조성물 및 키트
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EP2776129B2 (en) 2011-11-10 2020-06-17 Kai Pharmaceuticals, Inc. Compositions for use in the treatment of chronic kidney disease-mineral bone disorder characterized by soft tissue calcification
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JP2015526423A (ja) 2012-07-25 2015-09-10 サイオクサス セラピューティクス リミテッド カヘキシア及びサルコペニアを治療するためのｓ−ピンドロールの使用
WO2014186809A2 (en) 2013-05-17 2014-11-20 The Translational Genomics Research Institute A genetic test to predict patient response to bone morphogenetic protein in arthrodesis
EP3425048A1 (en) 2014-01-24 2019-01-09 AM-Pharma B.V. Chimeric alkaline phosphatase-like proteins
ES2688066T3 (es) 2014-01-24 2018-10-30 Am-Pharma B.V. Procesamiento para recuperación y purificación de una fosfatasa alcalina
EP3845245B1 (en) 2014-06-09 2025-06-25 Ultragenyx Pharmaceutical Inc. The effective and efficient control of serum phosphate for optimal bone formation
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
EP3207132B1 (en) 2014-10-15 2019-07-31 Alexion Pharmaceuticals, Inc. Methods of shifting an isoelectric profile of a protein product and uses thereof
ES3038086T3 (en) 2014-12-05 2025-10-09 Alexion Pharma Inc Treating seizure with recombinant alkaline phosphatase
EP3250227A2 (en) 2015-01-28 2017-12-06 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
KR101867134B1 (ko) 2015-03-23 2018-06-12 한양대학교 산학협력단 포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017171871A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
ES2887573T3 (es) 2016-06-27 2021-12-23 Alexion Pharma Inc Métodos para el tratamiento de la hipofosfatasia en niños y adolescentes
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
WO2018164995A1 (en) 2017-03-09 2018-09-13 Alexion Pharmaceuticals, Inc . Glycoprotein manufacturing process

Also Published As

Publication number Publication date
US20170360899A1 (en) 2017-12-21
RU2708068C2 (ru) 2019-12-04
RU2017123540A (ru) 2019-01-10
AU2015357551B2 (en) 2021-02-25
AU2015357551A1 (en) 2017-05-25
CN107405390A (zh) 2017-11-28
ES3038086T3 (en) 2025-10-09
MX2017007392A (es) 2019-01-24
US10449236B2 (en) 2019-10-22
CA2967851A1 (en) 2016-06-09
MX389350B (es) 2025-03-19
EP3226891B1 (en) 2025-06-25
RU2017123540A3 (enExample) 2019-07-17
JP2018502836A (ja) 2018-02-01
KR20240045379A (ko) 2024-04-05
CO2017005034A2 (es) 2017-08-31
BR112017011900A2 (pt) 2018-02-27
EP3226891A1 (en) 2017-10-11
US11224638B2 (en) 2022-01-18
CA2967851C (en) 2024-02-27
KR20170095278A (ko) 2017-08-22
US20200093898A1 (en) 2020-03-26
WO2016090251A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
JP6787894B2 (ja) 組換えアルカリホスファターゼを用いた発作の処置
EP2662448B1 (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
JP5986986B2 (ja) 基質石灰化障害を治療する方法、組成物、およびキット
JP7482914B2 (ja) ホモシスチン尿症の治療する組成物および方法
AU2018270925A1 (en) Recombinant human acid alpha-glucosidase
Riillo et al. c. 376A> G,(p. Ser126Gly) Alpha-Galactosidase A mutation induces ER stress, unfolded protein response and reduced enzyme trafficking to lysosome: Possible relevance in the pathogenesis of late-onset forms of Fabry Disease
BR122024007742A2 (pt) Uso de fosfatase alcalina recombinante no tratamento de ataques
JPWO2007000884A1 (ja) 骨・関節疾患の予防・治療剤およびそのスクリーニング方法
US20100077493A1 (en) Genes and pathways involved in bipolar disorder
Mohammad et al. ENPP1 Deficiency: A Shared Pathway in Hypophosphatemia, Rickets and Autoimmune Rheumatic Diseases
HK1191372B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
Garg Lipodystrophies: new genes, new insights
HK1141047B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
HK1162589B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170731

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200929

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201029

R150 Certificate of patent or registration of utility model

Ref document number: 6787894

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250